| # | Title | Journal | Year | Citations |
|---|
| 1 | The cancer/testis genes: review, standardization, and commentary | Cancer Immunity | 2004 | 384 |
| 2 | Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer | Cancer Immunity | 2007 | 224 |
| 3 | CTLA-4 blockade in tumor models: an overview of preclinical and translational research | Cancer Immunity | 2013 | 220 |
| 4 | Monoclonal antibodies in cancer therapy | Cancer Immunity | 2012 | 206 |
| 5 | NKG2D ligands as therapeutic targets | Cancer Immunity | 2013 | 168 |
| 6 | Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma | Cancer Immunity | 2010 | 165 |
| 7 | Efficiency of recombinant human TNF in human cancer therapy | Cancer Immunity | 2006 | 147 |
| 8 | Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma | Cancer Immunity | 2009 | 131 |
| 9 | The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases | Cancer Immunity | 2008 | 128 |
| 10 | Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin | Cancer Immunity | 2007 | 127 |
| 11 | Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice | Cancer Immunity | 2002 | 125 |
| 12 | Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients | Cancer Immunity | 2007 | 107 |
| 13 | Database of T cell-defined human tumor antigens: the 2013 update | Cancer Immunity | 2013 | 107 |
| 14 | Cancer/testis (CT) antigens - a new link between gametogenesis and cancer | Cancer Immunity | 2001 | 107 |
| 15 | Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression | Cancer Immunity | 2001 | 107 |
| 16 | Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma | Cancer Immunity | 2007 | 102 |
| 17 | Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha | Cancer Immunity | 2007 | 91 |
| 18 | Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials | Cancer Immunity | 2010 | 89 |
| 19 | T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein | Cancer Immunity | 2007 | 87 |
| 20 | Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease | Cancer Immunity | 2003 | 80 |
| 21 | DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer | Cancer Immunity | 2007 | 76 |
| 22 | Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients | Cancer Immunity | 2008 | 76 |
| 23 | Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers | Cancer Immunity | 2008 | 75 |
| 24 | Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma | Cancer Immunity | 2006 | 73 |
| 25 | Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors | Cancer Immunity | 2007 | 71 |
| 26 | Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin | Cancer Immunity | 2005 | 71 |
| 27 | CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours | Cancer Immunity | 2009 | 62 |
| 28 | Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells | Cancer Immunity | 2004 | 62 |
| 29 | Translating basic mechanisms of IgG effector activity into next generation cancer therapies | Cancer Immunity | 2012 | 58 |
| 30 | The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand | Cancer Immunity | 2004 | 58 |
| 31 | The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy | Cancer Immunity | 2009 | 57 |
| 32 | Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory | Cancer Immunity | 2003 | 57 |
| 33 | Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma | Cancer Immunity | 2009 | 56 |
| 34 | Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer | Cancer Immunity | 2007 | 56 |
| 35 | Identification of CT46/HORMAD1, an immunogenic cancer/testis antigen encoding a putative meiosis-related protein | Cancer Immunity | 2005 | 56 |
| 36 | PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses | Cancer Immunity | 2007 | 51 |
| 37 | Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients | Cancer Immunity | 2008 | 51 |
| 38 | Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on | Cancer Immunity | 2012 | 51 |
| 39 | Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma | Cancer Immunity | 2013 | 51 |
| 40 | Identification of the HERV-K gag antigen in prostate cancer by SEREX using autologous patient serum and its immunogenicity | Cancer Immunity | 2008 | 50 |
| 41 | Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer | Cancer Immunity | 2007 | 50 |
| 42 | The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma | Cancer Immunity | 2004 | 50 |
| 43 | Expression of cancer-testis (CT) antigens in placenta | Cancer Immunity | 2007 | 49 |
| 44 | Digital expression profiles of human endogenous retroviral families in normal and cancerous tissues | Cancer Immunity | 2004 | 49 |
| 45 | Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer | Cancer Immunity | 2008 | 48 |
| 46 | Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas | Cancer Immunity | 2008 | 43 |
| 47 | Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients | Cancer Immunity | 2013 | 43 |
| 48 | Expression of cancer-testis genes in human hepatocellular carcinomas | Cancer Immunity | 2002 | 43 |
| 49 | Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded | Cancer Immunity | 2005 | 42 |
| 50 | Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells | Cancer Immunity | 2005 | 42 |
